| Q61758719 | A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis |
| Q61050093 | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). |
| Q90763281 | A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! |
| Q29618851 | A gain-of-function mutation of JAK2 in myeloproliferative disorders |
| Q79797463 | A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients |
| Q54401759 | A novel germline JAK2 mutation in familial myeloproliferative neoplasms. |
| Q33411637 | A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea |
| Q53127891 | A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. |
| Q53312448 | A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. |
| Q43237567 | A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process |
| Q36873306 | Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms |
| Q44161637 | Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. |
| Q53663088 | Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. |
| Q43242613 | Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies |
| Q44119338 | Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. |
| Q87132122 | Balancing efficacy and safety of JAK inhibitors in myelofibrosis |
| Q42984351 | Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. |
| Q57786564 | Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients |
| Q33385885 | Blast phase of essential thrombocythemia: A single center study |
| Q46366679 | Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. |
| Q51452739 | Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. |
| Q81812223 | Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients |
| Q46889570 | Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations |
| Q29998841 | CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons |
| Q113387319 | COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey |
| Q98726025 | COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey |
| Q55070583 | Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. |
| Q61758699 | Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases |
| Q41095829 | Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy |
| Q50519906 | Classification of myeloproliferative neoplasms and prognostic factors. |
| Q38242725 | Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) |
| Q81753494 | Clinical findings and diagnosis in a case of cholangiocellular carcinoma in a horse |
| Q38046322 | Clinical predictors of outcome in MPN. |
| Q37059441 | Clinical relevance of JAK2 (V617F) mutant allele burden |
| Q44302357 | Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes |
| Q61758703 | Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm |
| Q45028996 | Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders |
| Q79157129 | Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders |
| Q54541956 | Clinical, serological and molecular investigations of EHV-1 and EHV-4 in 15 unweaned thoroughbred foals. |
| Q44836127 | Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma |
| Q81091504 | Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment |
| Q45142769 | Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. |
| Q33393245 | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status |
| Q34750599 | Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. |
| Q92149183 | Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) |
| Q54426186 | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. |
| Q101334417 | Direct-acting Antivirals in Hepatitis C Virus-positive Mantle Cell Lymphomas |
| Q93336832 | Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma |
| Q81943294 | Disease anticipation in familial myeloproliferative neoplasms |
| Q54504237 | Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. |
| Q33413428 | Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients |
| Q53166045 | Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. |
| Q46908433 | Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. |
| Q33502512 | Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma. |
| Q51030605 | Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. |
| Q39869997 | Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group |
| Q43280900 | Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations |
| Q35794393 | European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment |
| Q33420346 | Everolimus in diffuse large B-cell lymphomas |
| Q52656928 | Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases. |
| Q61758726 | Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation |
| Q90027063 | Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure |
| Q42852415 | Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. |
| Q61050089 | Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression |
| Q42389394 | Germline RBBP6 mutations in familial myeloproliferative neoplasms. |
| Q80206218 | HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia |
| Q40247865 | Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy |
| Q84333293 | High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma |
| Q50510659 | How I treat polycythemia vera. |
| Q97069845 | How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey |
| Q54544165 | How to manage polycythemia vera. |
| Q53281116 | Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. |
| Q38174710 | Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper |
| Q46698681 | Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma |
| Q53851430 | Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. |
| Q35634902 | Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. |
| Q90541890 | Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group |
| Q53096529 | Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. |
| Q57718877 | Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas |
| Q53126695 | Improving survival trends in primary myelofibrosis: an international study. |
| Q61627770 | In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology |
| Q37934479 | Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. |
| Q53298023 | Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. |
| Q84146542 | Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia |
| Q42639007 | Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. |
| Q28222209 | Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation |
| Q54536225 | Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. |
| Q38434473 | Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma |
| Q38246159 | It is time to change thrombosis risk assessment for PV and ET? |
| Q92622295 | Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative |
| Q87472427 | JAK inhibitor in CALR-mutant myelofibrosis |
| Q34150008 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations |
| Q51784812 | JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. |
| Q61758730 | JAK2 (V617F) mutation in healthy individuals |
| Q53136481 | Leukemia risk models in primary myelofibrosis: an International Working Group study. |
| Q46621424 | Leukemic transformation of polycythemia vera: a single center study of 23 patients |
| Q47785142 | Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients |
| Q80996436 | Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia |
| Q37127245 | Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. |
| Q79330558 | Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up |
| Q44919951 | Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman |
| Q33843390 | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls |
| Q48333259 | Looking for CALR mutations in familial myeloproliferative neoplasms. |
| Q50980949 | Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma. |
| Q51618906 | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| Q50528661 | Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. |
| Q41892144 | Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus. |
| Q58910044 | Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation |
| Q34216205 | Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. |
| Q37763236 | Mutational status of myeloproliferative neoplasms. |
| Q54348167 | Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. |
| Q46334118 | Myelofibrotic transformation in essential thrombocythemia. Author reply. |
| Q43844466 | New and old prognostic factors in polycythemia vera |
| Q34634950 | New generation small-molecule inhibitors in myeloproliferative neoplasms. |
| Q38716316 | New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. |
| Q79802927 | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment |
| Q38896683 | New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma |
| Q82892014 | Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination |
| Q82481917 | Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders |
| Q39431412 | Novel agents in indolent lymphomas. |
| Q48301978 | PDGFRB disease: right diagnosis to prolong survival |
| Q61758744 | PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia |
| Q38416243 | Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis |
| Q37163590 | Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. |
| Q43910566 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. |
| Q46755036 | Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases |
| Q100533856 | Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis |
| Q33386154 | Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. |
| Q33963986 | Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. |
| Q33385644 | Pomalidomide is active in the treatment of anemia associated with myelofibrosis |
| Q43142224 | Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia |
| Q43033054 | Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. |
| Q88220591 | Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy |
| Q43035212 | Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. |
| Q46722601 | Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. |
| Q53279276 | Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. |
| Q43898090 | Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. |
| Q33432755 | Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. |
| Q80866784 | Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment |
| Q61792035 | Pulmonary rhodococcosis in a cat |
| Q83452377 | RBC-transfusion guidelines update |
| Q34451630 | Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS |
| Q54625613 | Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. |
| Q37412790 | Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. |
| Q36907860 | Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. |
| Q79476945 | Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy |
| Q79901768 | Role of the molecular staging and response in the management of follicular lymphoma patients |
| Q54320183 | Ruxolitinib and survival improvement in patients with myelofibrosis. |
| Q42702330 | Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results |
| Q38393343 | Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. |
| Q33420037 | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. |
| Q92583848 | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| Q46913469 | Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders |
| Q42982069 | Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles |
| Q51793429 | Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. |
| Q92089359 | Stem cell transplant in MF: it's time to personalize |
| Q42992127 | Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. |
| Q37900078 | Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. |
| Q83147038 | Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients |
| Q40129814 | Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. |
| Q47805811 | The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera |
| Q48680927 | The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients |
| Q39857628 | The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group |
| Q33411211 | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis |
| Q73062445 | Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity |
| Q28210858 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman |
| Q42223101 | Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients |
| Q56964532 | Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms |
| Q48082828 | Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia |
| Q54683377 | Validation of cytogenetic-based risk stratification in primary myelofibrosis. |
| Q53180804 | Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. |
| Q59620003 | What are RBC-transfusion-dependence and -independence? |